Medication works best with nutrition, movement, and follow-up care
NICE guidance recognises that maintaining weight loss is itself a significant clinical achievement, as most individuals regain weight after stopping obesity treatments
The appropriateness of semaglutide, including dose and duration, must be determined through a medical evaluation
She calls it a whole new way to manage weight
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity
Healthcare Provider Support Not all healthcare providers may be on board with microdosing
